Compare TDY & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDY | INSM |
|---|---|---|
| Founded | 1960 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1B | 35.2B |
| IPO Year | 2000 | 2000 |
| Metric | TDY | INSM |
|---|---|---|
| Price | $646.95 | $139.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 23 |
| Target Price | ★ $650.33 | $188.73 |
| AVG Volume (30 Days) | 258.2K | ★ 2.0M |
| Earning Date | 04-22-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.70 | N/A |
| EPS | ★ 18.88 | N/A |
| Revenue | ★ $1,020,400,000.00 | N/A |
| Revenue This Year | $5.52 | $168.46 |
| Revenue Next Year | $5.08 | $65.97 |
| P/E Ratio | $34.76 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $419.00 | $60.40 |
| 52 Week High | $693.38 | $212.75 |
| Indicator | TDY | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 36.04 |
| Support Level | $525.76 | $136.62 |
| Resistance Level | $674.63 | $167.01 |
| Average True Range (ATR) | 16.73 | 5.31 |
| MACD | -6.80 | -0.62 |
| Stochastic Oscillator | 21.48 | 11.13 |
Teledyne Technologies Inc provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability. The firm operates in four segments: Digital Imaging, Instrumentation, Aerospace and Defense Electronics, and Engineered Systems. The Digital Imaging segment, that derives maximum revenue, includes high-performance sensors, cameras and systems, within the visible, infrared and X-ray spectra for use in industrial, government and medical applications, as well as MEMS and high-performance, high-reliability semiconductors including analog-to-digital and digital-to-analog converters. Geographically, the company operates in United States, Europe, Asia, and All other.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.